Beam Therapeutics Inc. Share Price & Technical Analysis
BEAM · $28.64 (+3.51%)
Healthcare / Biotechnology
$28.64
+3.51%
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targe…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-5% return in May, -2% avg return in past 3 year May month.
11% return in 2026, 13% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -1% | 4% | -13% | 26% | -5% | – | – | – | – | – | – | – | 11% |
| 25 | 4% | 5% | -26% | 2% | -21% | 6% | 17% | -14% | 50% | 3% | 2% | 12% | 41% |
| 24 | -10% | 61% | -17% | -36% | 12% | -3% | 34% | -14% | -7% | -10% | 23% | -9% | 24% |
| 23 | 9% | -9% | -23% | 1% | 4% | 0% | -3% | -24% | 3% | -12% | 31% | -3% | -27% |
| 22 | -13% | 11% | -26% | -35% | -6% | 9% | 62% | -5% | -11% | -10% | 2% | -16% | -39% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Uptrend · Neutral
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$3.18B
P/E ratio
—
52W high
$36.44
52W low
$15.35
Volume
13,27,424
Beta
2.26
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Beam Therapeutics Inc. share price today?
- Beam Therapeutics Inc. (BEAM) last traded around $28.64 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does BEAM have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for BEAM. Download the app for real-time alerts.
- How can I analyze Beam Therapeutics Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.